Loading…

Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1

Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon‐like peptide‐1 (GLP‐1), a gut incretin hormone, has become a well‐established treatment for T2DM and is likely to be involved in treating cognitive impairment....

Full description

Saved in:
Bibliographic Details
Published in:The European journal of neuroscience 2021-11, Vol.54 (10), p.7749-7769
Main Authors: Liu, Xiao‐Yu, Zhang, Ni, Zhang, Sheng‐Xiao, Xu, Ping
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon‐like peptide‐1 (GLP‐1), a gut incretin hormone, has become a well‐established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP‐1‐based therapeutics in AD.
ISSN:0953-816X
1460-9568
DOI:10.1111/ejn.15502